A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
(2021)
Journal Article
Fox, C. P., Ali, A. S., McIlroy, G., Thust, S., Martinez-Calle, N., Jackson, A. E., …Cwynarski, K. (2021). A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20), 4073-4082. https://doi.org/10.1182/bloodadvances.2021004779
Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.